医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MabPlex Announces Expansion of cGMP Manufacturing Facilities

2016年10月04日 PM08:00
このエントリーをはてなブックマークに追加


 

FREMONT, Calif. & YANTAI, China

MabPlex International Ltd. (MabPlex), a global CRO/CMO service provider specializing in the development and manufacturing of antibody therapeutics and antibody-drug conjugates (ADC), today announced that it has broken ground on the expansion of its biomanufacturing facilities in China. The current 275,000 sq. ft. facility will soon be running at full capacity. In order to effectively serve customers better MabPlex is expanding their current CDMO facility. The new 428,000 sq. ft. facility is expected to be completed by August of 2017. The Utility and HVAC validation should be finished by December 2017 and the fill/finish facility will be completely validated by March of 2018. “With this expansion we believe that we will be able to meet our customers’ needs in biologics for the foreseeable future,” says Qibin Liang, President of MabPlex.

The current 275,000 sq. ft. facility will be entirely converted to ADC manufacturing and development space while the new 428,000 sq. ft. facility will be for mAb and other biologic manufacturing. This expansion will allow for six complete 2,000L bioreactor suites or 6 independent manufacturing lines (6x25L, 6x200L, 6x500L and 12×2,000L single use bioreactors). Six purification suites, a 37,000sq ft. cGMP Warehouse, and fill finish lines with capabilities up to 10,000 vials/hr. for mAb and 12,000 vials/hr. for ADC will be housed in these new buildings.

About MabPlex

MabPlex, founded in 2013, specializes in providing one-stop biologics development and manufacturing solutions to customers globally with our services from cell line development and process development to GMP manufacturing. Our technical expertise allows us to provide effective and high-quality solutions for monoclonal antibody and ADC therapeutics to the biopharmaceutical industry. With this, MabPlex delivers our commitment to our partners through our quality manufacturing, meeting their expectations.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005500/en/

CONTACT

MabPlex USA, Inc.
Bethanne Deuel, MBA, 1-800-925-3608
Director
of Marketing and Communications
bdeuel@us.mabplex.com
www.mabplex.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Ancillare Announces New Vice President of Asia-Pacific
  • Invest in Sharjah Begins Participation Tomorrow (December 7) at Free Trade and Special Economic Zone Summit Shanghai 2016
  • Amano Dental Clinic(日本)推出由一线牙医开发的刷牙应用“Brush’n'Save”,旨在让女儿远离龋齿
  • Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting
  • 新成立的Cerevance以新技术、药物阵容和3600万美元现金来抗击脑病